Neon Bloom, Inc. (NBCO)
USD 0.01
(-7.0%)
USD 0.01
(-7.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -632.4 Thousand USD | -47.54% |
| 2022 | -428.62 Thousand USD | 70.93% |
| 2021 | -1.47 Million USD | -2323.14% |
| 2020 | -60.84 Thousand USD | 99.7% |
| 2019 | -20.52 Million USD | -4420.23% |
| 2018 | -454.06 Thousand USD | 15.39% |
| 2017 | -536.67 Thousand USD | -1266130.18% |
| 2016 | -42.38 USD | 0.0% |
| 2010 | -1.63 Million USD | -561.49% |
| 2009 | -246.49 Thousand USD | -168.32% |
| 2008 | 360.77 Thousand USD | 129.53% |
| 2007 | -1.22 Million USD | -2751.07% |
| 2006 | -42.84 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -21.08 Thousand USD | 94.68% |
| 2024 Q2 | -1.55 Million USD | -7283.47% |
| 2023 Q2 | 6212.00 USD | 113.51% |
| 2023 Q1 | -45.99 Thousand USD | -144.58% |
| 2023 Q4 | -396.42 Thousand USD | -102.05% |
| 2023 FY | -632.4 Thousand USD | -47.54% |
| 2023 Q3 | -196.2 Thousand USD | -3258.4% |
| 2022 Q1 | -109.09 Thousand USD | 91.04% |
| 2022 FY | -428.62 Thousand USD | 70.93% |
| 2022 Q4 | -18.8 Thousand USD | -134.3% |
| 2022 Q3 | 54.83 Thousand USD | 115.42% |
| 2022 Q2 | -355.56 Thousand USD | -225.93% |
| 2021 Q4 | -1.21 Million USD | -877.73% |
| 2021 Q3 | -124.55 Thousand USD | -136.07% |
| 2021 Q2 | -52.76 Thousand USD | 32.85% |
| 2021 Q1 | -78.56 Thousand USD | -3732.63% |
| 2021 FY | -1.47 Million USD | -2323.14% |
| 2020 Q3 | -39.61 USD | 0.0% |
| 2020 FY | -60.84 Thousand USD | 99.7% |
| 2020 Q4 | -2050.00 USD | -5075.46% |
| 2019 FY | -20.52 Million USD | -4420.23% |
| 2018 FY | -454.06 Thousand USD | 15.39% |
| 2017 Q3 | -8.99 USD | 0.0% |
| 2017 FY | -536.67 Thousand USD | -1266130.18% |
| 2017 Q4 | -8.99 USD | 0.0% |
| 2016 FY | -42.38 USD | 0.0% |
| 2016 Q3 | -6.26 USD | 0.0% |
| 2016 Q4 | -6.26 USD | 0.0% |
| 2015 Q4 | -3.53 USD | 0.0% |
| 2015 Q3 | -3.53 USD | 0.0% |
| 2011 Q1 | -77.37 Thousand USD | 91.17% |
| 2010 Q1 | -309.52 Thousand USD | -334.72% |
| 2010 Q2 | -162.35 Thousand USD | 47.55% |
| 2010 Q3 | -287.13 Thousand USD | -76.86% |
| 2010 Q4 | -876.61 Thousand USD | -205.29% |
| 2010 FY | -1.63 Million USD | -561.49% |
| 2009 Q2 | -151.19 Thousand USD | -152.09% |
| 2009 FY | -246.49 Thousand USD | -168.32% |
| 2009 Q4 | -71.2 Thousand USD | -321.73% |
| 2009 Q3 | 32.11 Thousand USD | 121.24% |
| 2009 Q1 | -59.97 Thousand USD | 40.57% |
| 2008 Q4 | -100.91 Thousand USD | -290.93% |
| 2008 FY | 360.77 Thousand USD | 129.53% |
| 2008 Q3 | -25.81 Thousand USD | 63.88% |
| 2008 Q2 | -71.46 Thousand USD | -112.79% |
| 2008 Q1 | 558.97 Thousand USD | 179.43% |
| 2007 Q1 | -54.27 Thousand USD | 0.0% |
| 2007 Q2 | -186.4 Thousand USD | -243.44% |
| 2007 Q3 | -277.13 Thousand USD | -48.67% |
| 2007 Q4 | -703.71 Thousand USD | -153.92% |
| 2007 FY | -1.22 Million USD | -2751.07% |
| 2006 FY | -42.84 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 52.644% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 90.943% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 101.194% |
| Nascent Biotech, Inc. | -2.08 Million USD | 69.708% |
| Rebus Holdings, Inc. | -1.02 Million USD | 37.999% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 100.971% |
| Qrons Inc. | -789.34 Thousand USD | 19.882% |
| Adynxx, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 98.99% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -52.212% |
| Skye Bioscience, Inc. | -37.64 Million USD | 98.32% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 99.156% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 90.383% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -131.31% |
| SQZ Biotechnologies Company | -79.46 Million USD | 99.204% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 78.136% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 65.262% |
| Mesoblast Limited | -87.95 Million USD | 99.281% |
| Marizyme, Inc. | -65.34 Million USD | 99.032% |
| Genus plc | 7.9 Million USD | 108.005% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 94.194% |
| Pharming Group N.V. | -10.54 Million USD | 94.004% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 70.854% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 82.955% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 92.849% |
| ContraFect Corporation | -65.15 Million USD | 99.029% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 87.057% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 63.391% |
| IMV Inc. | -36.48 Million USD | 98.267% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 92.153% |
| MultiCell Technologies, Inc. | -380.07 USD | -166292.244% |
| ONE Bio Corp. | 8.67 Million USD | 107.289% |
| Accustem Sciences Inc. | -3.74 Million USD | 83.12% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 98.777% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | 50.092% |
| Q BioMed Inc. | -2.05 Million USD | 69.182% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 83.059% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 73.438% |
| Biomind Labs Inc. | -1.21 Million USD | 47.921% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 98.941% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 79.611% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 91.998% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 67.556% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -4122.803% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 96.015% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 89.129% |
| GB Sciences, Inc. | -1.36 Million USD | 53.557% |
| Alpha Cognition Inc. | -13.77 Million USD | 95.408% |
| HST Global, Inc. | -146.21 Thousand USD | -332.533% |
| CSL Limited | 2.64 Billion USD | 100.024% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 63.961% |
| Halberd Corporation | -79.67 Thousand USD | -693.723% |
| Enzolytics Inc. | -2.17 Million USD | 70.948% |
| Agentix Corp. | -1.37 Million USD | 53.98% |
| Resverlogix Corp. | -3.61 Million USD | 82.482% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 80.059% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.786% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 745.313% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 109.133% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 84.082% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 79.102% |
| AVAX Technologies, Inc. | -6.41 Million USD | 90.14% |
| Zenith Capital Corp. | -10.59 Million USD | 94.032% |
| Genscript Biotech Corporation | -95.47 Million USD | 99.338% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -2620.966% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 84.746% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -946.328% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 68.46% |
| Kadimastem Ltd | -3.3 Million USD | 80.879% |
| Helix BioMedix, Inc. | -1.05 Million USD | 40.116% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 83.441% |
| BioStem Technologies, Inc. | -8.48 Million USD | 92.545% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -43.283% |
| LadRx Corporation | 400.44 Thousand USD | 257.927% |
| Cell Source, Inc. | -5.32 Million USD | 88.115% |
| Regen BioPharma, Inc. | 1.02 Million USD | 161.788% |
| Regen BioPharma, Inc. | 1.02 Million USD | 161.788% |
| NovAccess Global Inc. | -4.76 Million USD | 86.74% |
| Affymax, Inc. | -14.42 Million USD | 95.616% |
| Itoco Inc. | -1.86 Million USD | 66.163% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 85.765% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 62.109% |
| Mobile Lads Corp. | -2.26 Million USD | 72.058% |
| CytoDyn Inc. | -49.84 Million USD | 98.731% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -700.181% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -177.217% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 32.832% |
| SYBLEU INC | -180.3 Thousand USD | -250.745% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 60.787% |
| International Stem Cell Corporation | -131 Thousand USD | -382.753% |
| Bioxytran, Inc. | -4.28 Million USD | 85.224% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -1065.255% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 75.006% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 98.684% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 70.085% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | 19.014% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 80.038% |
| Neutra Corp. | -233.46 Thousand USD | -170.879% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 96.883% |
| PureTech Health plc | -65.69 Million USD | 99.037% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 97.026% |
| IXICO plc | -1.17 Million USD | 46.315% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 93.629% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 98.893% |
| CSL Limited | 2.64 Billion USD | 100.024% |
| Cellectis S.A. | -103.17 Million USD | 99.387% |